Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Statera Biopharma, Inc. Announces Institutional Review Board Approves Study of STAT-205 for Acute COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Statera Biopharma Announces FDA Lifts Clinical Hold on Entolimod","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Statera Biopharma Submits Phase 3 Clinical Trial Protocol to FDA for Investigational\u00a0Treatment of Pediatric Crohn\u2019s Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"EF Hutton","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Statera Biopharma Announces Closing of $2.0 Million Registered Direct Offering","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$6.0 million","newsHeadline":"Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Immune Therapeutics","pharmaFlowCategory":"D","amount":"$402.0 million","upfrontCash":"$2.0 million","newsHeadline":"Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Statera Biopharma","sponsor":"Lay Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Statera Biopharma

    Menu

    Statera Biopharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Statera Biopharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products

              Details:

              The agreement allows Statera the right to supply the IgY products for the existing approved markets. Statera also receives the right to license and commercialize current and future products for other indications.

              Lead Product(s): Avian Antibody

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Recipient: Lay Sciences

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership May 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Statera Biopharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone

              Details:

              Statera will receive milestones, new indications and royalties, Crohn’s disease and COVID-19 indications and regulatory approvals, payments from Immune Therapeutics in exchange for Statera’s rights to any product containing low-dose naltrexone as an active ingredient.

              Lead Product(s): Naltrexone Hydrochloride

              Therapeutic Area: Infections and Infectious Diseases Product Name: STAT-205

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Immune Therapeutics

              Deal Size: $402.0 million Upfront Cash: $2.0 million

              Deal Type: Agreement April 27, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Statera Biopharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod

              Details:

              Under the terms of the definitive agreement, Statera will receive upfront payment and revenue-based milestone payments from Coeptis in exchange for Statera’s rights to any product containing Entolimod as an active ingredient and all other related TLR5 agonists.

              Lead Product(s): Entolimod

              Therapeutic Area: Oncology Product Name: CBLB502

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Coeptis Therapeutics

              Deal Size: Undisclosed Upfront Cash: $6.0 million

              Deal Type: Agreement April 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Statera Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19

              Details:

              STAT-205 may show promise in treating both acute COVID infections and long COVID in this manner. Preliminary in vitro data demonstrated the drug’s ability to slow or halt the progression of SARS-CoV-2 (the virus that causes COVID-19) in human lung cells.

              Lead Product(s): Naltrexone Hydrochloride

              Therapeutic Area: Infections and Infectious Diseases Product Name: STAT-205

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Statera Biopharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Statera Biopharma Announces Closing of $2.0 Million Registered Direct Offering

              Details:

              This financing will be used for general corporate purposes, including the Company’s Phase 3 pediatric Crohn’s study for STAT-201, its acute COVID study, as well as other development activities.

              Lead Product(s): STAT-201

              Therapeutic Area: Gastroenterology Product Name: STAT-201

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: EF Hutton

              Deal Size: $2.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering February 09, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Statera Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Statera Biopharma Submits Phase 3 Clinical Trial Protocol to FDA for Investigational Treatment of Pediatric Crohn’s Disease

              Details:

              STAT-201, Statera’s most advanced drug candidate, in Phase 2 study demonstrated proof of concept and safety as well as remission in 67% of participants and 43% of true mucosal healing with endoscopies.

              Lead Product(s): STAT-201

              Therapeutic Area: Gastroenterology Product Name: STAT-201

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 29, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Statera Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Statera Biopharma Announces FDA Lifts Clinical Hold on Entolimod

              Details:

              Statera is establishing a development program in Oncology and Hematology based on the potential that toll-like receptor 5 agonists, such as Entolimod, have shown in the treatment of neutropenia and anemia in cancer patients.

              Lead Product(s): Entolimod

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: STAT-600

              Highest Development Status: Undisclosed Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 01, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Statera Biopharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Statera Biopharma, Inc. Announces Institutional Review Board Approves Study of STAT-205 for Acute COVID-19

              Details:

              During preclinical in vitro studies, STAT-205 demonstrated an ability to inhibit the replication of coronaviruses in human lung cells. Data also shows that STAT-205 could prevent life-threatening lung inflammation caused by COVID-19, as well as lessen the risk of reinfection.

              Lead Product(s): STAT-205

              Therapeutic Area: Infections and Infectious Diseases Product Name: STAT-205

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 19, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY